Paper36588702
Progress of potential drugs targeted in lipid metabolism research.
Liang K and 1 other. Front Pharmacol, 2022. Cited by 32 papers, by iCite.
Cite this record
ConductScience Library. Progress of potential drugs targeted in lipid metabolism research. Papers, record 36588702. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36588702
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References203
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 9693110 | The role of ATP citrate-lyase in the metabolic regulation of plasma lipids. Hypolipidaemic effects of SB-204990, a lactone prodrug of the potent ATP citrate-lyase inhibitor SB-201076. | Biochem J | 1998 | https://conductscience.org/library/papers/9693110 | PubMed |
| 2 | 34635855 | ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: two parallel, placebo-controlled, randomized phase 2a trials. | Nat Med | 2021 | https://conductscience.org/library/papers/34635855 | PubMed |
| 3 | 31848472 | Mechanisms and regulation of cholesterol homeostasis. | Nat Rev Mol Cell Biol | 2020 | https://conductscience.org/library/papers/31848472 | PubMed |
| 4 | 32526482 | Acetyl-CoA Carboxylase Inhibition Improves Multiple Dimensions of NASH Pathogenesis in Model Systems. | Cell Mol Gastroenterol Hepatol | 2020 | https://conductscience.org/library/papers/32526482 | PubMed |
| 5 | 9395280 | Cerivastatin: pharmacology of a novel synthetic and highly active HMG-CoA reductase inhibitor. | Atherosclerosis | 1997 | https://conductscience.org/library/papers/9395280 | PubMed |
| 6 | 32711004 | Lipids and cancer: Emerging roles in pathogenesis, diagnosis and therapeutic intervention. | Adv Drug Deliv Rev | 2020 | https://conductscience.org/library/papers/32711004 | PubMed |
| 7 | 22608962 | Identification, optimisation and in vivo evaluation of oxadiazole DGAT-1 inhibitors for the treatment of obesity and diabetes. | Bioorg Med Chem Lett | 2012 | https://conductscience.org/library/papers/22608962 | PubMed |
| 8 | 8619885 | RP 64477: a potent inhibitor of acyl-coenzyme A:cholesterol O-acyltransferase with low systemic bioavailability. | Biochem Pharmacol | 1996 | https://conductscience.org/library/papers/8619885 | PubMed |
| 9 | 29674640 | The CPT1a inhibitor, etomoxir induces severe oxidative stress at commonly used concentrations. | Sci Rep | 2018 | https://conductscience.org/library/papers/29674640 | PubMed |
| 10 | 1718686 | Pravastatin. A review of its pharmacological properties and therapeutic potential in hypercholesterolaemia. | Drugs | 1991 | https://conductscience.org/library/papers/1718686 | PubMed |
| 11 | 11806796 | Withdrawal of cerivastatin from the world market. | Curr Control Trials Cardiovasc Med | 2001 | https://conductscience.org/library/papers/11806796 | PubMed |
| 12 | 35775133 | Inclisiran: A First-in-Class siRNA Therapy for Lowering Low-Density Lipoprotein Cholesterol. | Ann Pharmacother | 2023 | https://conductscience.org/library/papers/35775133 | PubMed |
| 13 | 29296668 | Chemical Proteomics Identifies SLC25A20 as a Functional Target of the Ingenol Class of Actinic Keratosis Drugs. | ACS Cent Sci | 2017 | https://conductscience.org/library/papers/29296668 | PubMed |
| 14 | 30448414 | Small molecules as inhibitors of PCSK9: Current status and future challenges. | Eur J Med Chem | 2019 | https://conductscience.org/library/papers/30448414 | PubMed |
| 15 | 34407950 | Structures of dimeric human NPC1L1 provide insight into mechanisms for cholesterol absorption. | Sci Adv | 2021 | https://conductscience.org/library/papers/34407950 | PubMed |
| 16 | 32433613 | Structure of nevanimibe-bound tetrameric human ACAT1. | Nature | 2020 | https://conductscience.org/library/papers/32433613 | PubMed |
| 17 | 35427476 | Identification and evaluation of a lipid-lowering small compound in preclinical models and in a Phase I trial. | Cell Metab | 2022 | https://conductscience.org/library/papers/35427476 | PubMed |
| 18 | 30909726 | Preservation of Acyl Coenzyme A Attenuates Pathological and Metabolic Cardiac Remodeling Through Selective Lipid Trafficking. | Circulation | 2019 | https://conductscience.org/library/papers/30909726 | PubMed |
| 19 | 29651165 | The mitochondrial citrate carrier, SLC25A1, drives stemness and therapy resistance in non-small cell lung cancer. | Cell Death Differ | 2018 | https://conductscience.org/library/papers/29651165 | PubMed |
| 20 | 2306268 | Inhibition of acyl coenzyme A: cholesterol acyl transferase by trimethylcyclohexanylmandelate (cyclandelate). | Biochem Pharmacol | 1990 | https://conductscience.org/library/papers/2306268 | PubMed |
Cited by19
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 32 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42756334 | Unravelling Ferroptosis in Sepsis: A Comprehensive Integrative Transcriptomic Analysis Across Age and Disease Severity. | Bioinform Biol Insights | 2026 | https://conductscience.org/library/papers/42756334 | PubMed |
| 42620423 | Stevia-derived sweeteners in reduced-sugar foods: formulation strategies, sensory optimization, nutritional evidence, and safety perspectives. | Front Nutr | 2026 | https://conductscience.org/library/papers/42620423 | PubMed |
| 42525264 | Fatty acids metabolic reprogramming and tumor microenvironment in pancreatic cancer: targeting pathways. | Clin Exp Med | 2026 | https://conductscience.org/library/papers/42525264 | PubMed |
| 42307183 | Pharmacologic Alteration of Meibum Lipid Composition Alleviates Dry Eye Phenotype in Awat2-/- Mice. | Invest Ophthalmol Vis Sci | 2026 | https://conductscience.org/library/papers/42307183 | PubMed |
| 41810963 | Fatty acid transporter protein isoform 2 (FATP2) inhibitor lipofermata inhibits Zika virus replication and blocks fatty acid uptake in SH-SY5Y neuroblastoma cell line. | Microbiol Spectr | 2026 | https://conductscience.org/library/papers/41810963 | PubMed |
| 41778199 | Alterations in lipid metabolism and blood profile in gynecological cancers - potential strategies in diagnosis and treatment. | Front Physiol | 2026 | https://conductscience.org/library/papers/41778199 | PubMed |
| 41373990 | Lipid Metabolism-Signaling Crosstalk in Metabolic Disease and Aging: Mechanisms and Therapeutic Targets. | Nutrients | 2025 | https://conductscience.org/library/papers/41373990 | PubMed |
| 41345744 | Advanced multifunctional nano-delivery platform focusing on treating diseases related to lipid metabolism via targeted intervention in various lipid metabolic processes. | Mil Med Res | 2025 | https://conductscience.org/library/papers/41345744 | PubMed |
| 41107389 | Anti-dengue activity of a cellular lipid uptake inhibitor, lipofermata. | Sci Rep | 2025 | https://conductscience.org/library/papers/41107389 | PubMed |
| 40651594 | Time-restricted feeding mediated synchronization of circadian rhythms to sustain cardiovascular health. | J Mol Cell Cardiol | 2025 | https://conductscience.org/library/papers/40651594 | PubMed |
| 40639772 | Fatty acid binding protein 1 (FABP1) depletion promotes an oxidative metabolic shift in Caco-2 colorectal cancer cells. | Biochim Biophys Acta Mol Cell Biol Lipids | 2025 | https://conductscience.org/library/papers/40639772 | PubMed |
| 40498199 | Untargeted Metabolomics of Human Embryonic Kidney (HEK) Cell Line. | Methods Mol Biol | 2025 | https://conductscience.org/library/papers/40498199 | PubMed |
| 40382194 | Emerging pathways yielding opportunities for future treatments in pancreatic ductal adenocarcinoma. | Expert Opin Ther Targets | 2025 | https://conductscience.org/library/papers/40382194 | PubMed |
| 40231255 | The rising influence of lipid metabolism in lung cancer: a global research perspective. | Front Oncol | 2025 | https://conductscience.org/library/papers/40231255 | PubMed |
| 40207794 | Discovery of lignans as the effective inhibitors of CES1A alleviate lipid droplets formation. | J Enzyme Inhib Med Chem | 2025 | https://conductscience.org/library/papers/40207794 | PubMed |
| 40123481 | Non-Esterified Fatty Acid Profiles and Cause-Specific Mortality: The Cardiovascular Health Study. | J Clin Endocrinol Metab | 2025 | https://conductscience.org/library/papers/40123481 | PubMed |
| 40107354 | Mitochondrial fatty acid oxidation as the target for blocking therapy-resistance and inhibiting tumor recurrence: The proof-of-principle model demonstrated for ovarian cancer cells. | J Adv Res | 2026 | https://conductscience.org/library/papers/40107354 | PubMed |
| 37850554 | Time-restricted feeding regulates lipid metabolism under metabolic challenges. | Bioessays | 2023 | https://conductscience.org/library/papers/37850554 | PubMed |
| 37841917 | Lipid metabolism as a target for cancer drug resistance: progress and prospects. | Front Pharmacol | 2023 | https://conductscience.org/library/papers/37841917 | PubMed |
Genes36
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36588702
GET https://conductscience.org/api/papers/v1/36588702/references?page=2